Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1

被引:187
作者
Sampath, J
Sun, DX
Kidd, VJ
Grenet, J
Gandhi, A
Shapiro, LH
Wang, QJ
Zambetti, GP
Schuetz, JD
机构
[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA
[3] St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA
[4] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA
关键词
D O I
10.1074/jbc.M103429200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The most frequently expressed drug resistance genes, MDR1 and MRP1, occur in human tumors with mutant p53. However, it was unknown if mutant p53 transcriptionally regulated both MDR1 and MRP1. We demonstrated that mutant p53 did not activate either the MRP1 promoter or the endogenous gene. In contrast, mutant p53 strongly up-regulated the MDR1 promoter and expression of the endogenous MDR1 gene. Notably, cells that expressed either a transcriptionally inactive mutant p53 or the empty vector showed no endogenous MDR1 up-regulation. Transcriptional activation of the MDR1 promoter by mutant p53 required an Ets binding site, and mutant p53 and Ets-1 synergistically activated MDR1 transcription. Biochemical analysis revealed that Ets-1 interacted exclusively with mutant p53s in vivo but not with wild-type p53. These findings are the first to demonstrate the induction of endogenous MDR1 by mutant p53 and provide insight into the mechanism.
引用
收藏
页码:39359 / 39367
页数:9
相关论文
共 45 条
[1]   Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy [J].
Blandino, G ;
Levine, AJ ;
Oren, M .
ONCOGENE, 1999, 18 (02) :477-485
[2]   A family of drug transporters: The multidrug resistance-associated proteins [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1295-1302
[3]   p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: A molecular and immunohistochemical study [J].
Buttitta, F ;
Marchetti, A ;
Gadducci, A ;
Pellegrini, S ;
Morganti, M ;
Carnicelli, V ;
Cosio, S ;
Gagetti, O ;
Genazzani, AR ;
Bevilacqua, G .
BRITISH JOURNAL OF CANCER, 1997, 75 (02) :230-235
[4]   P-GLYCOPROTEIN IS NOT EXPRESSED IN A MAJORITY OF COLORECTAL CARCINOMAS AND IS NOT REGULATED BY MUTANT P53 IN-VIVO [J].
DEANGELIS, P ;
STOKKE, T ;
SMEDSHAMMER, L ;
LOTHE, RA ;
LEHNE, G ;
CHEN, Y ;
CLAUSEN, OPF .
BRITISH JOURNAL OF CANCER, 1995, 72 (02) :307-311
[5]   GAIN OF FUNCTION MUTATIONS IN P53 [J].
DITTMER, D ;
PATI, S ;
ZAMBETTI, G ;
CHU, S ;
TERESKY, AK ;
MOORE, M ;
FINLAY, C ;
LEVINE, AJ .
NATURE GENETICS, 1993, 4 (01) :42-46
[6]   Enterocyte differentiation is compatible with SV40 large T expression and loss of p53 function in human colonic Caco-2 cells - Status of the pRb1 and pRb2 tumor suppressor gene products [J].
Djelloul, S ;
ForgueLafitte, ME ;
Hermelin, B ;
Mareel, M ;
Bruyneel, E ;
Baldi, A ;
Giordano, A ;
Chastre, E ;
Gespach, C .
FEBS LETTERS, 1997, 406 (03) :234-242
[7]  
FAN SJ, 1994, CANCER RES, V54, P5824
[8]   Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein [J].
Farmer, G ;
Friedlander, P ;
Colgan, J ;
Manley, JL ;
Prives, C .
NUCLEIC ACIDS RESEARCH, 1996, 24 (21) :4281-4288
[9]  
Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO
[10]  
2-P